{"nctId":"NCT00097981","briefTitle":"A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma","startDateStruct":{"date":"2005-01"},"conditions":["Multiple Myeloma"],"count":225,"armGroups":[{"label":"Thalidomide + dexamethasone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Thalidomide","Drug: Dexamethasone"]},{"label":"Thalidomide + dexamethasone + DOXIL","type":"EXPERIMENTAL","interventionNames":["Drug: Thalidomide","Drug: Dexamethasone","Drug: DOXIL"]}],"interventions":[{"name":"Thalidomide","otherNames":[]},{"name":"Dexamethasone","otherNames":[]},{"name":"DOXIL","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Previously untreated, histologically confirmed multiple myeloma (per International Myeloma Working Group \\[IMWG\\] criteria\n* Eastern Cooperative Oncology Group (ECOG) status 0-2\n* Adequate absolute neutrophil count (ANC), platelet count and hemoglobin\n* Adequate serum calcium\n* Enrollment in System for Thalidomide Education and Prescribing Safety Program (S.T.E.P.S.)\n\nExclusion Criteria:\n\n* No treatment with dexamethasone for multiple myeloma\n* No peripheral neuropathy of Grade 2 or higher\n* No Left Ventricular Ejection Fraction (LVEF) of less than 45 percentage\n* No history of life-threatening thromboembolic events of any kind (ie, myocardial infarction, pulmonary embolism, stroke or others), within 1 year before enrollment in the study\n* No deep vein thrombosis (DVT) within 1 year of enrollment\n* No current anticoagulation for DVT","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Complete Response Rate: Number of Participants Who Achieved a Complete Response","description":"Complete response rate to study medication is defined as number of participants who acheived complete response by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + plus no increase in size or number of lytic bone lesions. Complete response was assessed at the beginning of every treatment cycle prior to treatment, starting at Cycle 2.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response: Number of Participants Who Achieved a Complete Response (CR) or Partial Response (PR)","description":"Overall response to study medication is defined as number of participants who acheived a complete response (CR) or partial response (PR) by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + plus no increase in size or number of lytic bone lesions; and PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"76","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to 1st Response","description":"Time to first response was defined as the interval from date of randomization to date of achieving a partial response (PR) or better according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Progression","description":"Time to progression is the interval between the date of randomization until disease progression or death due to progression.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"584","spread":null},{"groupId":"OG001","value":"408","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival: Number of Participants Died Due to Any Cause","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Transplantation: Number of Participants Who Underwent Transplantation (Peripheral Stem Cell / Bone Marrow)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Engraftment: Number of Participants Who Underwent Engraftment","description":"Engraftment is the process of transplanted stem cells reproducing new cells.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":48,"n":110},"commonTop":["Fatigue","Oedema Peripheral","Constipation","Nausea","Anaemia"]}}}